This page shows the latest edoxaban news and features for those working in and with pharma, biotech and healthcare.
Eliquis (apixaban), Bayer/Johnson &Johnson's Xarelto (rivaroxaban) and Daiichi Sankyo's Lixiana/Savaysa (edoxaban) - have thus far not been approved.
Savaysa (edoxaban) some way behind in third and fourth place, respectively.
edoxaban). Xarelto has slipped from a 60%-plus market share, however, with Eliquis gaining ground in part because of a debate about Xarelto's role in stroke prevention and the design
Johnson &Johnson's Xarelto (rivaroxaban) or Daiichi Sankyo's Savaysa (edoxaban) - as well as generic indirect inhibitor enoxaparin. ... from the company on manufacturing as well as the inclusion of recently-approved edoxaban and enoxaparin on the label.
Squibb's Eliquis (apixaban) and Daiichi Sankyo's recently-approved Savaysa (edoxaban).
and Daiichi Sankyo's Savaysa (edoxaban) in both atrial fibrillation (AF) and venous thromboembolism (VTE), according to the company.
More from news
Approximately 6 fully matching, plus 25 partially matching documents found.
trial. Edoxaban. Edoxaban (Lixiana; Daiichi Sankyo) is an oral, once-daily, selective factor Xa inhibitor approved in Japan for prevention of VTE following major orthopaedic surgery. ... Daiichi Sankyo is conducting a large, worldwide, phase III trial of
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...